Editas Medicine (EDIT) Stock Price, Quote & News

Company Profile

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalasse...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 401 9000

Website: www.editasmedicine.com

Address:

11 Hurley Street, Cambridge, United States

1GreenDay99RedDays Apr. 28 at 8:27 PM

$EDIT $NTLA $CRSP There's the 10% drop to counter my truthful point that I expected.

0 · Reply

ERadar Apr. 28 at 8:20 PM

$EDIT

0 · Reply

doctorwho Apr. 28 at 5:25 PM

$ASTS just a little bit more - patience 🧘‍♂️ Selling $EDIT and buying Asts tomorrow at $71 a share Then will sell Asts to buy $RVI and playing ping pong between rvi and ast

0 · Reply

NinjaXLightning Apr. 28 at 4:18 PM

$ONDS The online ONDS hype feels very similar to $ACHR before it collapsed from over 10 to 5s. I bought ONDS in low 1s, and ACHR is low 3s. Didn’t hit tip top on either but made good multiples. I am currently loading $EDIT and $TREE before major reversals. Buy when it’s quiet, sell when it’s loud.

1 · Reply

NewEarth Apr. 28 at 12:01 PM

$BEAM $CRBU $CRSP $EDIT $JNJ

0 · Reply

ERadar Apr. 28 at 2:53 AM

$EDIT

0 · Reply

NinjaXLightning Apr. 27 at 2:19 PM

$NTLA Major squeeze is about to occur with $EDIT, could easily be next $JAZZ over coming 3-5 years. Intellia will start paying royalties to Editas. $XBI

0 · Reply

NinjaXLightning Apr. 27 at 1:43 PM

$NTLA With this news, I expect $EDIT will soon announce royalty deal with fresh money coming from Intellia.

0 · Reply

svertical1 Apr. 27 at 5:36 AM

$IBRX $NTLA $CRSP $EDIT Great example of how HF roaches operate…. Friday to Sunday…

0 · Reply

jewell69 Apr. 26 at 3:21 PM

$NTLA b mid morning 15.16 4/24 after hours close 16.26 So surprised I don’t own anything else $EDIT $CRSP $QURE $EDIT Was this move in these ( not QURE ) enough to move the needle on $XBI

0 · Reply

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

Mar 27, 2026, 7:00 AM EDT - 4 weeks ago

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Mar 12, 2026, 8:30 AM EDT - 6 weeks ago

Editas Medicine Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 9, 2026, 7:00 AM EDT - 7 weeks ago

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Mar 2, 2026, 10:30 AM EST - 2 months ago

Editas Medicine Transcript: TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 9:00 AM EST - 2 months ago

Editas Medicine to Participate in Upcoming Investor Conferences

Jan 19, 2026, 2:20 AM EST - 3 months ago

Genflow Biosciences PLC Announces Directorate Change

Dec 2, 2025, 9:10 AM EST - 5 months ago

Editas Medicine Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 10, 2025, 7:00 AM EST - 6 months ago

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

Nov 3, 2025, 9:00 AM EST - 6 months ago

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

Oct 21, 2025, 8:45 AM EDT - 6 months ago

Editas Medicine Transcript: Chardan’s 9th Annual Genetic Medicines Conference

Oct 14, 2025, 7:00 AM EDT - 7 months ago

Editas Medicine Transcript: H. C. Wainwright Genetic Medicines Virtual Conference

Oct 9, 2025, 11:01 AM EDT - 7 months ago

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Oct 6, 2025, 9:00 AM EDT - 7 months ago

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

Sep 4, 2025, 11:30 AM EDT - 8 months ago

Editas Medicine Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 8:00 AM EDT - 8 months ago

Editas Medicine Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 2, 2025, 8:00 AM EDT - 8 months ago

Editas Medicine Transcript: Status Update

Sep 2, 2025, 7:00 AM EDT - 8 months ago

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

Aug 28, 2025, 4:01 PM EDT - 8 months ago

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

Aug 12, 2025, 4:01 PM EDT - 9 months ago

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

Jun 12, 2025, 2:01 AM EDT - 11 months ago

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

May 14, 2025, 9:31 AM EDT - 1 year ago

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

May 14, 2025, 7:01 AM EDT - 1 year ago

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting

May 13, 2025, 8:15 PM EDT - 1 year ago

Editas Medicine Transcript: BofA Securities 2025 Healthcare Conference

May 13, 2025, 7:01 AM EDT - 1 year ago

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

May 12, 2025, 4:30 PM EDT - 1 year ago

Editas Medicine Announces First Quarter 2025 Results and Business Updates

May 12, 2025, 4:01 PM EDT - 1 year ago

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

May 5, 2025, 4:01 PM EDT - 1 year ago

Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

Apr 28, 2025, 4:31 PM EDT - 1 year ago

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Mar 20, 2025, 4:01 PM EDT - 1 year ago

Editas Medicine Announces Chief Financial Officer Transition

Mar 11, 2025, 9:00 AM EDT - 1 year ago

Editas Medicine Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 10, 2025, 9:20 AM EDT - 1 year ago

Editas Medicine Transcript: Leerink’s Global Healthcare Conference 2025

Mar 5, 2025, 4:05 PM EST - 1 year ago

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

Mar 3, 2025, 2:30 PM EST - 1 year ago

Editas Medicine Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 24, 2025, 9:00 AM EST - 1 year ago

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

Jan 15, 2025, 2:15 PM EST - 1 year ago

Editas Medicine Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Jan 6, 2025, 9:00 AM EST - 1 year ago

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 13, 2024, 6:44 AM EST - 1 year ago

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026

Dec 12, 2024, 6:03 PM EST - 1 year ago

Editas to reduce about 65% of its workforce over the next six months

Dec 12, 2024, 5:00 PM EST - 1 year ago

Editas Medicine Transcript: Strategy Update

Dec 12, 2024, 4:00 PM EST - 1 year ago

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Dec 9, 2024, 12:00 PM EST - 1 year ago

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Dec 3, 2024, 1:20 PM EST - 1 year ago

Editas Medicine Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 25, 2024, 12:59 PM EST - 1 year ago

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts

Nov 19, 2024, 1:50 PM EST - 1 year ago

Editas Medicine Transcript: Stifel 2024 Healthcare Conference

Nov 4, 2024, 7:30 AM EST - 1 year ago

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Editas Medicine Transcript: Strategy Update

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Editas Medicine Transcript: Strategy Update

Oct 21, 2024, 4:30 PM EDT - 1 year ago

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

Oct 18, 2024, 4:01 PM EDT - 1 year ago

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

Oct 7, 2024, 3:33 PM EDT - 1 year ago

Editas Medicine (EDIT) Shares Plunge Amid Biotech Sector Fluctuations

Oct 3, 2024, 6:00 PM EDT - 1 year ago

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

Oct 1, 2024, 3:45 PM EDT - 1 year ago

Editas Medicine Transcript: Chardan Genetic Medicines Conference

Sep 17, 2024, 1:20 PM EDT - 1 year ago

Editas Medicine Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 5, 2024, 4:30 PM EDT - 1 year ago

Editas Medicine Transcript: 2024 Wells Fargo Healthcare Conference

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Editas Medicine Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Editas Medicine Earnings Call Transcript: Q2 2024

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Editas Medicine Announces Second Quarter 2024 Results and Business Updates

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update

Jun 14, 2024, 3:01 AM EDT - 2 years ago

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

Jun 14, 2024, 3:00 AM EDT - 2 years ago

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress

May 30, 2024, 8:30 AM EDT - 2 years ago

Editas Medicine Transcript: AGM 2024

May 15, 2024, 2:05 PM EDT - 2 years ago

Editas Medicine Transcript: RBC Capital Markets 2024 Global Healthcare Conference

May 14, 2024, 10:00 AM EDT - 2 years ago

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June

May 10, 2024, 6:00 AM EDT - 2 years ago

Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting

May 8, 2024, 8:00 AM EDT - 2 years ago

Editas Medicine Earnings Call Transcript: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Editas Medicine Announces First Quarter 2024 Results and Business Updates

May 2, 2024, 7:00 AM EDT - 2 years ago

Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events

May 1, 2024, 8:00 AM EDT - 2 years ago

Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration

Apr 22, 2024, 4:31 PM EDT - 2 years ago

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Mar 13, 2024, 2:05 PM EDT - 2 years ago

Editas Medicine Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Mar 12, 2024, 10:40 AM EDT - 2 years ago

Editas Medicine Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 4, 2024, 12:50 PM EST - 2 years ago

Editas Medicine Transcript: TD Cowen 44th Annual Health Care Conference 2024

Feb 28, 2024, 8:00 AM EST - 2 years ago

Editas Medicine Earnings Call Transcript: Q4 2023

Feb 28, 2024, 7:00 AM EST - 2 years ago

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates

Feb 21, 2024, 7:00 AM EST - 2 years ago

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events

Feb 13, 2024, 8:40 AM EST - 2 years ago

Editas Medicine Transcript: Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 9:30 AM EST - 2 years ago

Editas Medicine Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Jan 9, 2024, 7:30 PM EST - 2 years ago

Editas Medicine Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 8, 2024, 8:15 AM EST - 2 years ago

Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference

Jan 3, 2024, 7:00 AM EST - 2 years ago

Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 13, 2023, 9:00 AM EST - 2 years ago

Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9

Dec 11, 2023, 1:00 PM EST - 2 years ago

Editas Medicine Transcript: Study Update

Nov 28, 2023, 1:20 PM EST - 2 years ago

Editas Medicine Transcript: 6th Annual Evercore ISI HealthCONx Conference

Nov 3, 2023, 8:00 AM EDT - 2 years ago

Editas Medicine Earnings Call Transcript: Q3 2023

Sep 11, 2023, 10:00 AM EDT - 2 years ago

Editas Medicine Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Sep 7, 2023, 3:00 PM EDT - 2 years ago

Editas Medicine Transcript: Wells Fargo Securities Healthcare Conference 2023

Aug 2, 2023, 8:00 AM EDT - 2 years ago

Editas Medicine Earnings Call Transcript: Q2 2023

Jun 12, 2023, 8:00 AM EDT - 3 years ago

Editas Medicine Transcript: Study Result

May 9, 2023, 8:00 PM EDT - 3 years ago

Editas Medicine Transcript: Bank of America Securities 2023 Healthcare Conference

May 5, 2023, 8:00 AM EDT - 3 years ago

Editas Medicine Earnings Call Transcript: Q1 2023

Feb 22, 2023, 8:00 AM EST - 3 years ago

Editas Medicine Earnings Call Transcript: Q4 2022

Jan 10, 2023, 7:30 PM EST - 3 years ago

Editas Medicine Transcript: JPMorgan Healthcare Conference

Dec 6, 2022, 8:00 AM EST - 3 years ago

Editas Medicine Transcript: Study Update

Nov 17, 2022, 8:00 AM EST - 3 years ago

Editas Medicine Transcript: Study Update

Nov 2, 2022, 8:00 AM EDT - 3 years ago

Editas Medicine Earnings Call Transcript: Q3 2022

Aug 3, 2022, 10:15 AM EDT - 4 years ago

Editas Medicine Earnings Call Transcript: Q2 2022

May 4, 2022, 8:45 AM EDT - 4 years ago

Editas Medicine Earnings Call Transcript: Q1 2022

Feb 24, 2022, 6:36 AM EST - 4 years ago

Editas Medicine Earnings Call Transcript: Q4 2021

Nov 7, 2021, 7:00 PM EST - 4 years ago

Editas Medicine Earnings Call Transcript: Q3 2021

Sep 28, 2021, 8:00 PM EDT - 4 years ago

Editas Medicine Transcript: Study Result

Aug 4, 2021, 3:24 AM EDT - 5 years ago

Editas Medicine Earnings Call Transcript: Q2 2021

Jun 3, 2021, 8:30 AM EDT - 5 years ago

Editas Medicine Transcript: AGM 2021

May 5, 2021, 11:13 AM EDT - 5 years ago

Editas Medicine Earnings Call Transcript: Q1 2021

Feb 25, 2021, 8:00 AM EST - 5 years ago

Editas Medicine Earnings Call Transcript: Q4 2020

Nov 5, 2020, 5:00 PM EST - 5 years ago

Editas Medicine Earnings Call Transcript: Q3 2020

Aug 6, 2020, 5:00 PM EDT - 6 years ago

Editas Medicine Earnings Call Transcript: Q2 2020

Jun 10, 2020, 8:30 AM EDT - 6 years ago

Editas Medicine Transcript: AGM 2020

May 7, 2020, 8:00 AM EDT - 6 years ago

Editas Medicine Earnings Call Transcript: Q1 2020

Feb 26, 2020, 5:00 PM EST - 6 years ago

Editas Medicine Earnings Call Transcript: Q4 2019

Nov 12, 2019, 8:00 AM EST - 7 years ago

Editas Medicine Earnings Call Transcript: Q3 2019

Aug 6, 2019, 5:00 PM EDT - 7 years ago

Editas Medicine Earnings Call Transcript: Q2 2019

May 7, 2019, 5:00 PM EDT - 7 years ago

Editas Medicine Earnings Call Transcript: Q1 2019

1GreenDay99RedDays Apr. 28 at 8:27 PM

$EDIT $NTLA $CRSP There's the 10% drop to counter my truthful point that I expected.

0 · Reply

ERadar Apr. 28 at 8:20 PM

$EDIT

0 · Reply

doctorwho Apr. 28 at 5:25 PM

$ASTS just a little bit more - patience 🧘‍♂️ Selling $EDIT and buying Asts tomorrow at $71 a share Then will sell Asts to buy $RVI and playing ping pong between rvi and ast

0 · Reply

NinjaXLightning Apr. 28 at 4:18 PM

1 · Reply

NewEarth Apr. 28 at 12:01 PM

$BEAM $CRBU $CRSP $EDIT $JNJ

0 · Reply

ERadar Apr. 28 at 2:53 AM

$EDIT

0 · Reply

NinjaXLightning Apr. 27 at 2:19 PM

$NTLA Major squeeze is about to occur with $EDIT, could easily be next $JAZZ over coming 3-5 years. Intellia will start paying royalties to Editas. $XBI

0 · Reply

NinjaXLightning Apr. 27 at 1:43 PM

$NTLA With this news, I expect $EDIT will soon announce royalty deal with fresh money coming from Intellia.

0 · Reply

svertical1 Apr. 27 at 5:36 AM

$IBRX $NTLA $CRSP $EDIT Great example of how HF roaches operate…. Friday to Sunday…

0 · Reply

jewell69 Apr. 26 at 3:21 PM

$NTLA b mid morning 15.16 4/24 after hours close 16.26 So surprised I don’t own anything else $EDIT $CRSP $QURE $EDIT Was this move in these ( not QURE ) enough to move the needle on $XBI

0 · Reply

NewEarth Apr. 26 at 1:21 PM

$CRSP $BEAM $JNJ $CRBU $EDIT

1 · Reply

WallStreetBuyDip Apr. 25 at 11:44 PM

$EDIT Trading around $2.90 after hitting highs near $4.15 and lows near $1.30. Volume averaging around 2.1 million, with recent pullback from $3.50S to $2.90S.

0 · Reply

svertical1 Apr. 25 at 4:01 PM

$IBRX $XBI $TNYA $EDIT Thanks jut1! One of the best reports I’ve ever read about Naked Shorting and how Hedge Funds make money. Funny, it talks about how HF’s can create counterfeit shares to suppress stock price indefinitely until a company ‘stumbles’. With IBRX (and others) I’m convinced HF’s had an inside track with someone in the FDA to insure the ‘stumble’ (CRL, RTF, Non-Ad Ad warning), then lined up the Law Firms and some in the media to attack. A must read nonetheless!!

3 · Reply

leon_dedrick Apr. 25 at 9:48 AM

$NTLA If these guys are successful Monday I think it will be more bullish for $EDIT thank any other company Why Just ask Google what licenses they hold!!!!

0 · Reply

LiveCommander Apr. 24 at 8:25 PM

$CRSP down 11% $NTLA down 14% $EDIT down 9% $BEAM down 10% $SGMO down 25%

0 · Reply

biotech Apr. 24 at 8:12 PM

$SGMO well nothing special here: $CRSP down 11% $NTLA down 14% $EDIT down 9% $BEAM down 10% $SGMO down 25%

2 · Reply

OfficialStocktwitsUser Apr. 24 at 6:27 PM

$EDIT RSI: 58.04, MACD: 0.2370 Vol: 0.41, MA20: 2.97, MA50: 2.49 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

1 · Reply

Frankness100 Apr. 24 at 4:57 PM

$EDIT hate to use that 'healthy pullback' cliche but obv the rsi was running hit. tough to know if it pulls back more, im leaning towards a bounce next week.

0 · Reply

Realy Apr. 24 at 2:14 PM

$EDIT a healthy pull back, and hope it’s not just wishful thinking…☕️🍵 $CRSP $NTLA $SGMO

0 · Reply

NinjaXLightning Apr. 22 at 3:04 PM

$EDIT $JAZZ Google AI says: Jazz Pharmaceuticals (JAZZ) saw its stock price rise from a historical low of $0.55 in April 2009 to over $200 by April 2026. This massive growth was driven by a transformation from a near-bankrupt, single-product startup into a diversified, high-margin rare disease powerhouse." Does that sound familiar to EDIT? I think so.

0 · Reply

harryvanluik Apr. 22 at 12:22 PM

$EDIT Yesterday was just a healthy pull-back after huge gains from the last week. Today we are ready to continue our flight: buckle-up and off we go!

1 · Reply

harryvanluik Apr. 22 at 6:34 AM

$EDIT any idea what caused this short-time pull-back?

1 · Reply

Market Cap	284.81M
Revenue (ttm)	40.52M
Net Income (ttm)	-160.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-395.01%
Debt to Equity Ratio	0.00

Volume	1,268,000
Avg Vol	1,702,084
Day's Range	N/A - N/A
Shares Out	97.87M
Stochastic %K	5%
Beta	2.04
Analysts	Sell
Price Target	$5.61